VITIELLO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 1.005
EU - Europa 629
AS - Asia 549
SA - Sud America 98
AF - Africa 11
OC - Oceania 1
Totale 2.293
Nazione #
US - Stati Uniti d'America 983
RU - Federazione Russa 420
SG - Singapore 247
CN - Cina 131
BR - Brasile 80
IT - Italia 80
HK - Hong Kong 50
VN - Vietnam 48
DE - Germania 30
FR - Francia 26
GB - Regno Unito 21
IN - India 18
CA - Canada 14
JP - Giappone 13
BD - Bangladesh 11
NL - Olanda 11
AR - Argentina 9
PL - Polonia 9
MX - Messico 7
ES - Italia 6
FI - Finlandia 6
SE - Svezia 6
SA - Arabia Saudita 5
ID - Indonesia 4
LT - Lituania 4
TR - Turchia 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
IQ - Iraq 3
BE - Belgio 2
BO - Bolivia 2
CO - Colombia 2
EG - Egitto 2
MA - Marocco 2
NP - Nepal 2
PK - Pakistan 2
TW - Taiwan 2
VE - Venezuela 2
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MD - Moldavia 1
MV - Maldive 1
PE - Perù 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
Totale 2.293
Città #
Dallas 730
Singapore 181
Moscow 75
Ashburn 50
Hong Kong 49
Beijing 38
San Jose 35
Los Angeles 21
Ho Chi Minh City 17
Munich 17
New York 17
Orem 15
Lauterbourg 14
Hanoi 12
Santa Clara 12
São Paulo 12
Milan 11
Tokyo 11
Montreal 9
Rome 9
Hefei 8
Poplar 8
Manchester 7
Warsaw 7
Bacoli 6
Frankfurt am Main 6
London 6
Phoenix 6
Shanghai 6
Stockholm 6
Brooklyn 5
Cesano Boscone 5
Chennai 5
Denver 5
Guangzhou 5
Chicago 4
Monza 4
Mumbai 4
Riyadh 4
Atlanta 3
Boardman 3
Boston 3
Da Nang 3
Dhaka 3
Helsinki 3
Houston 3
Johannesburg 3
Mexico City 3
Naples 3
Porto Alegre 3
Querétaro 3
Shenzhen 3
Tianjin 3
Toronto 3
Agadir 2
Amsterdam 2
Ankara 2
Bari 2
Belo Horizonte 2
Biên Hòa 2
Brussels 2
Chengdu 2
Cleveland 2
Colombo 2
Council Bluffs 2
Duque de Caxias 2
Forcalquier 2
Formosa 2
Fortaleza 2
Guarulhos 2
Helena 2
Jinhua 2
Lappeenranta 2
Nanning 2
New Delhi 2
Nuremberg 2
Pelotas 2
Pescara 2
Phủ Lý 2
San Francisco 2
Santa Fe 2
São José dos Campos 2
Trieste 2
Vignola 2
Wroclaw 2
Alexandria 1
Almirante Tamandaré 1
Alto Paraguai 1
Amstelveen 1
Annapolis 1
Antakya 1
Avaré 1
Bangkok 1
Barcelona 1
Barranquilla 1
Belford Roxo 1
Belgrade 1
Bishkek 1
Brasília 1
Brazzaville 1
Totale 1.564
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 424
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 417
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 115
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 112
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 102
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 97
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 92
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 91
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 91
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 90
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 84
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 83
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 77
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 73
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 70
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 69
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 68
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 66
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 63
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 57
null 7
Immunotherapy in small bowel adenocarcinoma: a potential role? 4
Unleashing precision: A review of targeted approaches in pleural mesothelioma 2
Totale 2.354
Categoria #
all - tutte 4.502
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.502


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202412 0 0 0 0 0 0 0 0 0 1 6 5
2024/2025117 6 0 0 3 8 10 11 16 5 5 10 43
2025/20262.225 114 390 489 231 176 79 105 159 406 76 0 0
Totale 2.354